Board of Directors
Matthew was appointed Chairman on June 18, 2008 and has been a member of the Board since March 12, 2003. He is also a member of the Nomination Committee. He was the Company’s Chief Executive Officer from March 2003 to June 2008.
Matthew brings to the Board his operational knowledge of Shire and his wealth of international sales, marketing, integration and operational experience in the pharmaceutical sector. Matthew is a Director of Vertex Pharmaceuticals Inc. He served as Chairman, CEO and President of Vertex Pharmaceuticals Inc. from 2009 until early 2012 and is a former Director of Incyte Corporation.
Matthew began his career in international pharmaceuticals with Merck & Co, Inc. in 1974, where he held a wide range of sales, marketing and administrative positions. In 1992, he helped to establish Astra Merck Inc., a joint venture between Merck and Astra AB of Sweden, becoming President and Chief Executive Officer. In 1999, he joined Merck KGaA and established EMD Pharmaceuticals, the company’s US prescription pharmaceutical business. He later served as President of Merck KGaA’s global prescription pharmaceuticals business in Germany. Matthew holds a degree in Business Management.
Flemming Ornskov, MD
Chief Executive Officer
Flemming assumed the position of Chief Executive Officer on April 30, 2013. He is a member of the Board of Directors and is also a member of the Company’s Leadership Team.
Flemming brings to his position his operational and medical knowledge and his extensive international, strategic and operational experience in the pharmaceutical sector. He is Non-Executive Chairman of Evotec AG and is a former Non-Executive Director of PCI Biotech Holding ASA.
Flemming held the position of Chief Marketing Officer and Global Head, Strategic Marketing for General and Specialty Medicine at Bayer from 2010 to 2012. Prior to joining Bayer, Flemming served as Global President, Pharmaceuticals and OTC at Bausch & Lomb, Inc., from 2008 to 2010. He also served as Chairman and later as President and Chief Executive Officer of Life-Cycle Pharma A/S from 2006 to 2008, and President and Chief Executive Officer of Ikaria, Inc., from 2005 to 2006. Earlier in his pharmaceutical career he had roles of increasing responsibility at Merck & Co. Inc. and Novartis AG, following a distinguished period in hospital and academic medicine. Flemming received his MD from the University of Copenhagen, MBA from INSEAD, and Master of Public Health from Harvard University.
Chief Financial Officer
Graham has been the Chief Financial Officer and a member of the Board since July 1, 2008. He is also a member of the Leadership Team.
Graham brings to his position a broad range of international finance management and planning, audit, risk management and M&A experience. He was Chief Financial Officer of Bacardi in 2007 and Chief Financial Officer of Allied Domecq plc from 1999 to 2005. Graham is a Fellow of the Chartered Institute of Management Accountants.
Deputy Chairman and Senior Independent Non-Executive Director
David has been a member of the Board since April 5, 2004. He was appointed Senior Independent Non-Executive Director in July 2007 and Deputy Chairman in June 2008. He is also Chairman of the Nomination Committee and a member of the Audit, Compliance & Risk Committee.
David brings to the Board his extensive knowledge and experience in financial reporting, risk management and internal financial controls. He is a Non-Executive Director of InterContinental Hotels Group plc.
He was Chairman of Premier Foods plc until September 2010 and held directorships at Camelot Group plc and HMV Group plc. David retired from Cadbury Schweppes plc in April 2004 after serving as Chief Financial Officer since 1995. He worked for the Cadbury Schweppes Group between 1965 and 1984 and rejoined the company in 1989 following its acquisition of the Trebor Group, where he was Financial Director. David is a Fellow of the Chartered Institute of Management Accountants.
David was appointed to the Board on October 31, 2009 and is a member of the Audit, Compliance & Risk Committee and of the Remuneration Committee.
David brings to the Board extensive international sales, marketing, operational and supply chain experience gained in the pharmaceutical sector. He is a Director of Jabil Circuit, Inc. and Airgas Inc. and is a former Director of Allos Therapeutics, Inc.
David was President, Pharmaceutical Operations at GlaxoSmithKline, where he was responsible for the company’s global pharmaceutical operations, from January 2003 to February 2008. Prior to that, he was President of GlaxoSmithKline’s US Pharmaceuticals Business and before that SmithKline Beecham’s North American Pharmaceuticals Business. Before joining SmithKline Beecham, David worked for many years at Schering-Plough. David holds a BA in biology.
William was appointed to the Board on March 15, 2010 and is a member of the Remuneration Committee, the Nomination Committee and of the Science & Technology Committee.
William brings to the Board extensive experience in international sales, marketing, integration and operational experience in the pharmaceutical sector. He is a Director of Biotie Therapies Corp., Roche Holdings Ltd, Chugai Pharmaceutical Co., Ltd and Genentech, Inc. and is a former Director of Crucell N.V.
William worked for many years for Roche, holding the position of CEO of their pharmaceuticals division from 2005 to 2009 and was a member of the Roche Group Corporate Executive Committee. William holds a BA (Hons).
Dr. David Ginsburg
David was appointed to the Board on June 16, 2010 and is Chairman of the Science & Technology Committee.
David brings to the Board his clinical medical background in Internal Medicine, Hematology-Oncology, and Medical Genetics, as well as his extensive basic biomedical laboratory research expertise. He is currently James V. Neel Distinguished University Professor of Internal Medicine Human Genetics, and Pediatrics at the University of Michigan and a Howard Hughes Medical Institute Investigator. David obtained his BA at Yale University, MD at Duke University and completed his medical and research training at Harvard Medical School, before joining the faculty at the University of Michigan. David is the recipient of numerous honors and awards, including election to membership in the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.
Anne was appointed to the Board on June 16, 2010 and is Chairman of the Remuneration Committee and a member of the Nomination Committee.
Anne brings to the Board her extensive legal, commercial and remuneration experience. She is a Non-Executive Director of Tate & Lyle PLC and ExlService Holdings, Inc. and is a former Director of Northumbrian Water plc and SITA UK.
Anne held the position of Group Director, Human Resources at Centrica plc from October 2002 to 30 June 2011 and was a member of the Centrica Executive Committee. Her extensive business career includes senior management roles at Shell UK, the position of Deputy Director-General of the Engineering Employers’ Federation and the position of Group Director Human Resources at Smiths Group plc. Following her law degree at Aberdeen University and a postgraduate diploma in Human Resources she qualified as a lawyer. Anne is a Fellow of the Chartered Institute of Personnel & Development, the Royal Society of Arts and the London City and Guilds and a Member of Law Society of Scotland. She is a trustee of the University of Aberdeen Development Trust and is Patron of the University of Aberdeen Alumni Fund.
Susan was appointed to the Board on September 1, 2011 and is Chairman of the Audit, Compliance & Risk Committee.
Susan brings to the Board extensive M&A and finance experience. She is a Non-Executive Director of BBA Aviation plc and Coca-Cola HBC AG and is a former Director of Hong Kong listed global skin care company, L’Occitane International S.A. Susan has had a distinguished global career in investment banking having held senior positions with The First Boston Corporation, Bankers Trust, Barclays de Zoete Wedd and most recently Credit Suisse where she was Chairman of the EMEA Mergers & Acquisitions team until 2009 and continues in a part-time senior advisory capacity. Susan holds a BA in Economics and a MBA.
Dr. Steven Gillis
Steven was appointed to the Board on October 1, 2012 and is a member of the Science & Technology Committee and of the Remuneration Committee.
He brings to the Board his extensive technical and scientific knowledge and commercial experience. Steven is currently a Managing Director at ARCH Venture Partners, a provider of venture capital for technology firms, where he is focused on the evaluation of new life science technologies and the development and growth of ARCH’s biotechnology portfolio companies. Prior to this, Steven was a founder and director of Corixa Corporation, acquired by GlaxoSmithKline in 2005. Prior to starting Corixa, he was a founder and director of Immunex Corporation.
An immunologist by training, Steven has authored more than 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20) and the novel vaccine adjuvant, MPL.
Steven received his BA from Williams College and his Ph.D. from Dartmouth College.